Variational AI

Variational AI is a generative AI drug discovery company that provides the Enki platform for early-stage small molecule drug discovery. Enki generates optimized, synthesis-ready, lead-like compounds tailored to a target product profile, eliminating hit identification and hit-to-lead stages. It leverages generative AI to design novel molecular structures de novo, covering 873 pre-trained drug targets including kinases, GPCRs, proteases, and ion channels. The platform performs multiparameter optimization across 50+ parameters such as potency, selectivity, toxicity, ADMET, and synthetic accessibility. Users define a preclinical target product profile, Enki generates novel compounds, and researchers select candidates for synthesis and testing. Variational AI collaborates with pharma and biotech partners to accelerate discovery programs, aiming to improve unit economics and patient outcomes.

Key Benefits

• Generates novel structures not found using traditional methods
• Simultaneously optimizes across 50+ parameters
• Built specifically for early-stage small molecule drug discovery
• Moves beyond screening to de novo generation of compounds